UroGen Pharma (NASDAQ:URGN) reported its Q1 earnings results on Thursday, May 11, 2023 at 08:00 AM.
Here’s what investors need to know about the announcement.
Earnings
UroGen Pharma beat estimated earnings by 2.26%, reporting an EPS of $-1.3 versus an estimate of $-1.33.
Revenue was up $3.63 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.15 which was followed by a 8.9% drop in the share price the next day.
Here’s a look at UroGen Pharma’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -1.07 | -1.16 | -1.23 | -1.33 |
| EPS Actual | -1.22 | -1.13 | -1.18 | -1.25 |
| Revenue Estimate | 18.51M | 20.15M | 17.23M | 15.18M |
| Revenue Actual | 18.09M | 16.10M | 16.60M | 13.56M |
To track all earnings releases for UroGen Pharma visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
